As Abbott Laboratories prepares to get down to basics as a consumer-products company, it is pinning its emerging-market ambitions in part on turmeric. And cumin and chili. Abbott, which will split with its 124-year-old research-based drug division later this year, is shifting its focus from breakthrough medicines like arthritis treatment Humira, which command high prices in developed markets, to more basic products like nutrition supplements and generic drugs that can thrive in places like India, China and Vietnam.